1. Price Waterhouse Coopers. Pharma 2020: Virtual R&D, which path will you take? http://www.pwc.com/gx/en/pharma-life-sciences/pharma-2020/pharma2020-virtual-rd-which-path-will-you-take.jhtml. Published 2008. Accessed March 19, 2014.
2. Bjerrum OJ, Gautam Y, Honore PH, Vana V. Drug-drug combinations revisited. Eur J Hosp Pharm. 2014;21:8–12.
3. US Food and Drug Administration. Guidance for Industry: nonclinical safety evaluation of drug or biologic combinations. http://www.fda.gov/OHRMS/DOCKETS/98fr/05d-0004-gdl0002.pdf. Published 2006. Accessed March 18, 2014.
4. US Food and Drug Administration. Code of Federal Regulations Title 21, 21CFR3.2. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=3.2. Published 2013. Accessed March 19, 2014.
5. European Medicines Agency. Guideline on the non-clinical development of fixed combinations of medicinal products [EMEA/CHMP/SWP/258498/2005]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500003976.pdf. Published 2008. Accessed March 19, 2014.